Uzedy is a subcutaneous injection for the treatment of rheumatoid arthritis [1]. It is a biological medicine that works by targeting tumor necrosis factor (TNF) [1].
What is Uzedy's active ingredient?
Uzedy's active ingredient is etanercept [1]. Etanercept is a biologic drug that inhibits TNF, a protein that plays a role in inflammation [1].
How is Uzedy administered?
Uzedy is administered as a subcutaneous injection [1]. It is available in a prefilled autoinjector device [1].
Who is Uzedy approved for?
Uzedy is approved for adults with moderate to severe rheumatoid arthritis who have had an inadequate response to conventional disease-modifying antirheumatic drugs (DMARDs) [1]. It can be used alone or in combination with methotrexate or other DMARDs [1].
When did Uzedy receive FDA approval?
Uzedy received FDA approval on January 26, 2023 [2].
What are the potential side effects of Uzedy?
The most common side effects of Uzedy include injection site reactions, upper respiratory infections, headache, and fever [1]. Serious side effects can include infections, demyelinating disorders, heart failure, and blood disorders [1]. Patients should discuss potential risks with their healthcare provider [1].
How does Uzedy compare to other TNF inhibitors?
Uzedy contains etanercept, which is also the active ingredient in Enbrel [1]. Both medications are TNF inhibitors used for rheumatoid arthritis and other autoimmune conditions [1]. Differences in formulation or delivery device may exist between Uzedy and other etanercept products [1].
What is the patent status of Uzedy?
Information regarding specific patent expiration dates for Uzedy and its related intellectual property can be found through resources like DrugPatentWatch.com [3]. Patents protect the exclusivity of biologic drugs, influencing when generic or biosimilar versions may enter the market [3].